We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- In search of novel drugs against new targets
- The HIV replication cycle
- Cellular cofactors as novel antiviral targets
- Algorithm to identify and validate new cofactors (1)
- Algorithm to identify and validate new cofactors (2)
- Two novel integrase cofactors
- Identification of LEDGF: binding partner of integrase
- LEDGF/p75 identified by co-immunoprecipitation
- Lens epithelium-derived growth factor
- LEDGF properties
- Characterization of the interaction (1)
- Integrase and LEDGF co-localize in the nucleus
- LEDGF/p75 stimulates in vitro integrase activity
- LEDGF/p75 tethers HIV-1 IN to the chromatin
- Characterization of the interaction (2)
- Co-crystal structure
- Interface verified by mutagenesis
- The IBD of LEDGF is a protein playground
- Interaction of integrase, JPO2, pogZ with LEDGF
- Properties of LEDGF/p75 interaction partners
- Integrase-LEDGF interaction as antiviral target
- Role of LEDGF/p75 in HIV replication
- C-terminal fragments of LEDGF/p75
- HeLaP4 expressing C-terminal LEDGF fragments
- Molecular mechanism hypothesis of LEDGF/p75
- Potent inhibition of viral replication in HeLaP4 cells
- Selection of IBD-resistant strain (1)
- Selection of IBD-resistant strain (2)
- Integrase-LEDGF/p75 interaction-conclusions
- Assay and drug development
- Drug discovery (1)
- Drug discovery (2)
- Evaluation of HTS AlphaScreen assay
- Sources of compounds
- Rational design of LEDGINs
- From in silico towards in cellulo
- 2-(quinolin-3-yl)-acetic acids optimization
- Activity against HIV and SIV strains
- LEDGINs inhibit HIV replication at integration step
- LEDGINs profile as integrase inhibitors during TOA
- No cross-resistance with raltegravir
- Resistance selection to CX04328 (A128T)
- LEDGINs are allosteric integration inhibitors
- Part 1 conclusions
- TRN-SR2 as novel co-factor of HIV nuclear import
- Transportin-SR2 (TRN-SR2, TNPO3)
- siTRN-SR2 inhibits HIV-replication
- Studying nuclear import with GFP-labeled PICs
- Novel PIC nuclear import assay
- TRN-SR2 imports the PIC to the nucleus
- Final conclusions
- Acknowledgement
Topics Covered
- Cellular cofactors of HIV as novel antiviral targets
- LEDGF/p75 is a tethering factor of HIV integrase
- Identification of LEDGF/p75 as binding partner of integrase
- Characterization of the interaction
- Validation of integrase
- LEDGF/p75 interaction as antiviral target
- Assay and Drug Development
- Transportin
- SR2 is a nuclear import factor
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Debyser, Z. (2021, March 3). Cellular cofactors of HIV integrase: from target identification to discovery of ledgins [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/EXWH9558.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Zeger Debyser has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Update Available
The speaker addresses developments since the publication of the original talk. We recommend listening to the associated update as well as the lecture.
- Full lecture Duration: 51:35 min
- Update Interview Duration: 5:54 min
Cellular cofactors of HIV integrase: from target identification to discovery of ledgins
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
In the next presentation,
I will describe cellular co-factors of
the integrase of the human immunodeficiency virus (HIV).
I will discuss how we identified
novel targets and how this led to the discovery of new anti-HIV drugs,
the LEDGINs, that are inhibitors of the interaction
between HIV integrase and the co-factor LEDGF.
0:26
In the fight against HIV/AIDS,
we're still looking for novel anti-HIV drugs preferentially targeting new targets.
What are we looking for? We're looking for drugs,
new-virs that are associated with a high genetic barrier,
meaning that it will be difficult for the virus to become resistant against the drug.
There should be no cross-resistance with existing drugs on the market.
The compounds should be associated with no side-effects,
also not in the long term, since HIV causes chronic disease.
There should be optimal adherence, and this can be
accomplished by drugs that are only have to be taken once a day.
It should be produced at low cost so that it is also
affordable for people living in developing countries.
Last but not least,
we should at least consider the possibility of developing drugs that could lead to a cure,
to eradicate HIV from the blood of infected patients.
1:30
Here we illustrate the HIV replication cycle.
The HIV particle, via
its envelope proteins, will interact with the receptor and the co-receptor on
the target cell. After release of
the viral contents (RNA and proteins) reverse transcriptase will copy,
will retro-transcribe the RNA into a double-stranded DNA copy.
The copy, in the presence of
viral proteins and cellular proteins, should then be
transported into the nucleus through the nuclear pore,
where integrase will catalyze the integration of the insertion of
the pro-viral DNA into the genome of the host cell.
This is a point of no return.
After this step, the viral DNA will remain
present in the cell as long as it lives.
After cell division,
it will also transfer the viral DNA into the daughter cells.
From this pro-viral DNA
HIV proteins will be generated, and together with
RNA genomes new viral particles will arise.
Protease, through proteolytic cleavage, will then be involved in the maturation
of the viral proteins. After this step the viral particles become infectious.
As illustrated by the blue circle on the bottom of the slide,
my research group has been studying the integration process.
This is a complex process, it is taking place both in
the cytoplasm and the nucleus and involves many steps.
Integrase will bind to
the long terminal repeat ends of the viral DNA after completion of reverse transcription,
it is involved in importing the DNA into
the nucleus and then catalyzes the insertion of the DNA into the genome.
It has become clear in recent years (and this is
illustrated to the left) that these steps are taking
place within a protein-DNA complex
that we refer to as the 'pre-integration complex' (or the PIC).
This is composed of the viral DNA,
viral protein such as integrase matrix,
VPR, and also cellular proteins which we refer to as cellular co-factors.
The central theme of my research group is the insight that HIV
uses these cellular co-factors to achieve
its viral replication cycle, and also the integration step.
We consider these cellular co-factors as novel targets for anti-HIV drug discovery.
LEDGF/p75, a prototypical target within this concept, is highlighted in the cartoon.
Hide